Ideaya picks cancer drug candidate, targets human trial application in 2027

Phynart Studio
Ideaya Biosciences (IDYA) on Sunday said it selected IDE101 as a drug candidate for further development to treat cancers lacking CDKN2A, a gene that normally helps prevent uncontrolled cell growth. The company aims to seek U.S. regulatory permission to begin human testing
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.